Skip to main content
Hansa Biopharma logo

Hansa Biopharma — Investor Relations & Filings

Ticker · HNSA ISIN · SE0002148817 LEI · 549300LLEO25ZJJ3NT91 ST Manufacturing
Open in API
Filings indexed 499 across all filing types
Latest filing 2023-12-05 Regulatory Filings
Country SE Sweden
Listing ST HNSA

About Hansa Biopharma

https://www.hansabiopharma.com/

Hansa Biopharma is a commercial-stage biopharmaceutical company that develops and commercializes treatments for rare immunologic diseases. The company's core focus is its proprietary antibody-cleaving enzyme technology platform, designed to target and inactivate immunoglobulin G (IgG) antibodies. This approach aims to inhibit harmful IgG-mediated immune responses. Its lead product, imilfidase, is used to enable kidney transplantation in highly sensitized patients who have a low probability of finding a compatible donor. The company is also advancing its enzyme technology to address unmet medical needs in other therapeutic areas, including acute autoimmune diseases, gene therapy, and oncology, where IgG antibodies can be a barrier to treatment or a driver of the disease.

Recent filings

Filing Released Lang Actions
Hansa Biopharma planerar omstrukturering för att stärka den långsiktiga konkurrenskraften och tidigarelägga viktiga leveranser
Regulatory Filings Classification · 95% confidence The document is a 'PRESSMEDDELANDE' (Press Release) from Hansa Biopharma dated December 5, 2023. It announces a planned organizational restructuring, including workforce reduction and expected annual savings (75–85 MSEK). It also mentions initiating negotiations with unions and notifying the Public Employment Service. Crucially, it states that the information is disclosed pursuant to the EU Market Abuse Regulation (MAR). This type of announcement, detailing significant internal operational changes, restructuring, or strategic shifts that are material to the company's outlook, often falls under general regulatory disclosure or specific corporate actions. Since it is not a formal financial report (10-K, IR, ER), a management discussion (MDA), or a specific insider trade (DIRS), the most appropriate general category for a significant, non-financial-result-specific regulatory announcement is 'Regulatory Filings' (RNS), as it is a mandatory disclosure under MAR that doesn't fit the other specific categories like M&A, Capital Change, or Dividend Notice. Given the short length and nature as a press release announcing an internal action, RNS is the best fit among the provided options.
2023-12-05 Swedish
Hansa Biopharma plans restructuring to strengthen long-term competitiveness and advance key deliverables
Regulatory Filings Classification · 95% confidence The document is explicitly labeled as a "PRESS RELEASE" and announces a planned organizational restructuring, workforce reduction, and expected annual savings. It includes a statement that the information is made public pursuant to the EU Market Abuse Regulation and provides contact information for Investor Relations. This type of announcement, which details significant operational changes but is not a formal financial report (like 10-K or IR) or a specific transaction report (like DIRS or POS), fits best under the general category for regulatory announcements that don't fit elsewhere, which is Regulatory Filings (RNS). It is not an Earnings Release (ER) as it discusses restructuring, not financial results, and it is not a Call Transcript (CT) or Investor Presentation (IP).
2023-12-05 English
Hansa Biopharma meddelar att företagets Chief Financial Officer Donato Spota planerar att lämna sin tjänst
Board/Management Information Classification · 100% confidence The document is titled "PRESSMEDDELANDE" (Press Release) and announces that the Chief Financial Officer (CFO), Donato Spota, is planning to leave the company and that recruitment for a replacement is underway. This directly relates to changes in senior management/board composition. According to the definitions, 'Board/Management Information (Code: MANG)' covers the 'Announcement of changes in the company's board of directors or senior management.' The document is a short announcement, not a comprehensive report, confirming this classification.
2023-11-27 Swedish
Hansa Biopharma announces planned departure of Chief Financial Officer Donato Spota
Board/Management Information Classification · 100% confidence The document is explicitly titled 'PRESS RELEASE' and announces the 'planned departure of Chief Financial Officer Donato Spota'. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of Board/Management Information (MANG). The document is short and focuses solely on this personnel change, not on financial results or regulatory filings.
2023-11-27 English
Major Shareholding Notification 2023
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding percentage by a specific holder (Avanza Bank Holding AB for Avanza Pension) involving a 'Sell' transaction, resulting in a new total holding percentage (5.18163%). The structure, use of terms like 'major shareholding notification', 'voting rights', and the explicit mention of crossing a threshold ('Flaggning sker för passerat tröskelvärde') strongly indicate a regulatory filing related to significant ownership changes. This aligns perfectly with the definition of Major Shareholding Notification (MRQ). The document is not a full annual report (10-K), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2023-11-13 English
Major Shareholding Notification 2023
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding and voting rights for an instrument, specifically noting the 'Before the transaction' and 'After the transaction' quantities and percentages for Avanza Bank Holding AB concerning Hansa Biopharma AB shares. The content focuses on insider/significant shareholder transactions and resulting ownership percentages, which aligns directly with the definition of Director's Dealing or Major Shareholding Notification. Since the document explicitly details the resulting distribution of total holdings and voting rights after a transaction date (09/11/2023) and is published on 10/11/2023, it represents a notification of a change in significant share ownership crossing a threshold ('Flaggning sker för passerat tröskelvärde beträffande det aggregerade innehavet'). This strongly points to a Major Shareholding Notification (MRQ) rather than a Director's Dealing (DIRS), which typically focuses on executive trades. Given the structure and content, MRQ is the most precise fit.
2023-11-10 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.